Cameron Johnstone

Title: Cameron Johnstone: Innovator in Cancer Research

Introduction

Cameron Johnstone is a notable inventor based in Melbourne, Australia. He has made significant contributions to the field of cancer research, particularly in the development of isolated proteins and peptides that target colon cancer cells. His work has led to the filing of two patents that focus on innovative diagnostic and therapeutic methods.

Latest Patents

Cameron Johnstone's latest patents include "Isolated nucleic acid which encodes protein which binds to A33 antibody" and "Isolated protein which binds to A33 antibody, and peptides corresponding." These inventions relate to isolated proteins and peptides found on the surface of colon cells and colon cancer cells. The proteins and peptides bind to tumor-associated antibodies, such as mAb A33. The monomeric protein has a molecular weight of about 43 kD, as determined by SDS gel electrophoresis under non-reducing conditions. Furthermore, these inventions encompass the use of nucleic acid molecules and proteins in both monomeric and multimeric forms, as well as antibodies specific for the peptides in various diagnostic, screening, and therapeutic methods.

Career Highlights

Cameron Johnstone is affiliated with the Ludwig Institute for Cancer Research Limited, where he continues to advance his research in cancer biology. His work has been instrumental in understanding the interactions between proteins and antibodies, paving the way for new treatment options for cancer patients.

Collaborations

Some of Cameron's notable coworkers include Lloyd J Old and Sydney Welt. Their collaborative efforts contribute to the ongoing research and development in the field of cancer therapeutics.

Conclusion

Cameron Johnstone's innovative work in cancer research highlights the importance of targeted therapies in the fight against colon cancer. His patents reflect a commitment to advancing medical science and improving patient outcomes.